A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

This study tests a combination of two targeted drugs — sacituzumab govitecan (an antibody-drug conjugate) and cetuximab (a drug that blocks a cancer growth receptor) — in people with advanced or metastatic head and neck squamous cell cancer (HNSCC) whose cancer progressed after immunotherapy. **You may be eligible if...** - You have confirmed squamous cell cancer of the head and neck (mouth, throat, larynx, sinuses, or nasal cavity) that has spread or cannot be cured with surgery or radiation - Your cancer progressed after first-line treatment that included an immunotherapy drug (anti-PD-1/PD-L1 therapy), with or without chemotherapy - You have measurable disease on imaging **You may NOT be eligible if...** - Your cancer has not yet been treated with immunotherapy - You have significant organ dysfunction or other serious health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.